Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Tokushima, N/A, Japan
4
Total Recalls
0
Class I Recalls
4
Ongoing Recalls
Recalls by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
FDA Drug
Class III
Ongoing
Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13
April 9, 2024
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
N/A units
FDA Drug
Class III
Ongoing
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
April 9, 2024
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
108,192/30 count bottles or 7 count blister packs units
FDA Drug
Class III
Ongoing
Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.
April 9, 2024
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
N/A units
FDA Drug
Class III
Ongoing
Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13
April 9, 2024
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
N/A units